FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998839167> ?p ?o ?g. }

• W1998839167 endingPage "1239" @default.
• W1998839167 startingPage "1234" @default.
• W1998839167 abstract "No AccessJournal of UrologyAdult Urology1 Apr 2011Urinary PCA3 Score Predicts Prostate Cancer Multifocality Virginie Vlaeminck-Guillem, Marian Devonec, Marc Colombel, Claire Rodriguez-Lafrasse, Myriam Decaussin-Petrucci, and Alain Ruffion Virginie Vlaeminck-GuillemVirginie Vlaeminck-Guillem Department of Medical Unit of Molecular Oncology and Transfer, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France Institute of Functional Genomics of Lyon , Lyon, France More articles by this author , Marian DevonecMarian Devonec Department of Urology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France More articles by this author , Marc ColombelMarc Colombel Department of Urology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France More articles by this author , Claire Rodriguez-LafrasseClaire Rodriguez-Lafrasse Department of Medical Unit of Molecular Oncology and Transfer, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France More articles by this author , Myriam Decaussin-PetrucciMyriam Decaussin-Petrucci Department of Pathology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France Institute of Functional Genomics of Lyon , Lyon, France More articles by this author , and Alain RuffionAlain Ruffion Department of Urology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France Institute of Functional Genomics of Lyon , Lyon, France Financial interest and/or other relationship with Allergan, Ipsen, Takeda, Astra and Medtronic. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.11.072AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The urinary PCA3 gene test has proved helpful for deciding whether to (re)biopsy to diagnose prostate cancer. We searched for pathological features that influence the shedding of PCA3 producing prostate cancer cells in urine after digital rectal examination. Materials and Methods: Included in our study were 102 patients with an informative PCA3 score on the Progensa® PCA3 assay who underwent radical prostatectomy. Correlations were evaluated between PCA3 score and histopathological factors on prostatectomy, including tumor site in the prostate and the number of cancer foci. Results: PCA3 score significantly correlated with total tumor volume in prostatectomy specimens (p <0.001) but not with prostatectomy Gleason score or pathological stage. PCA3 score positively correlated with apical and basal invasion, and with bilaterality and multifocality. On multivariate analysis multifocality was an independent factor influencing PCA3 score (p = 0.012). Conclusions: Site in the prostate gland and the number of cancer foci may explain the observed PCA3 score variation in patients operated on for prostate cancer. The PCA3 test could be helpful in preoperatively selecting patients with unifocal and unilateral cancer who could benefit from active surveillance or focal therapy. References 1 : DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res1999; 59: 5975. Google Scholar 2 : DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res2002; 62: 2695. Google Scholar 3 : DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol2003; 44: 8. Google Scholar 4 : Urinary prostate cancer 3 test: toward the age of reason?. Urology2010; 75: 447. Google Scholar 5 : APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem2006; 52: 1089. Google Scholar 6 : The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res2007; 13: 939. Google Scholar 7 : PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology2007; 69: 532. Google Scholar 8 : PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol2008; 179: 1587. Link, Google Scholar 9 : Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol2008; 54: 1081. Google Scholar 10 : Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int2009; 103: 441. Google Scholar 11 : Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol2008; 10: 175. Google Scholar 12 : PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol2008; 179: 1804. Link, Google Scholar 13 : PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol2008; 180: 1975. Link, Google Scholar 14 : Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate2008; 68: 1215. Google Scholar 15 : Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate2010; 70: 10. Google Scholar 16 : A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol2003; 27: 1291. Google Scholar 17 : Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol1998; 160: 2407. Link, Google Scholar 18 : Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int2008; 101: 1513. Google Scholar 19 : Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can J Urol2006; 13: 2967. Google Scholar 20 : DD3(PCA3) gene expression in cancer and prostatic hyperplasia. Clin Invest Med2009; 32: E258. Google Scholar 21 : Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis. J Zhejiang Univ Sci B2007; 8: 853. Google Scholar 22 : Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol2007; 20: 1121. Google Scholar 23 : Expression of p65, DD3 and c-erbB2 genes in prostate cancer. Neoplasma2003; 50: 97. Google Scholar 24 : Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol2009; 6: 205. Google Scholar 25 : Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy—results from the SEARCH database. J Urol2007; 178: 1249. Link, Google Scholar 26 : Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?. BJU Int2009; 104: 195. Google Scholar 27 : Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int2010; 105: 1089. Google Scholar 28 : Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology2010; 76: 682. Google Scholar 29 : Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int2001; 88: 722. Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byChevli K, Duff M, Walter P, Yu C, Capuder B, Elshafei A, Malczewski S, Kattan M and Jones J (2018) Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate BiopsyJournal of Urology, VOL. 191, NO. 6, (1743-1748), Online publication date: 1-Jun-2014.Bradley L, Palomaki G, Gutman S, Samson D and Aronson N (2018) Comparative Effectiveness Review: Prostate Cancer Antigen 3 Testing for the Diagnosis and Management of Prostate CancerJournal of Urology, VOL. 190, NO. 2, (389-398), Online publication date: 1-Aug-2013.Gittelman M, Hertzman B, Bailen J, Williams T, Koziol I, Henderson R, Efros M, Bidair M and Ward J (2018) PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical StudyJournal of Urology, VOL. 190, NO. 1, (64-69), Online publication date: 1-Jul-2013. Volume 185Issue 4April 2011Page: 1234-1239 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Keywordshumanprostatic neoplasmsprostatectomybiologicalprostate cancer antigen 3prostatetumor markersAcknowledgmentsDr. F. Chapuis discussed the methodology, M. Cottancin and B. Grangier provided technical assistance and I. Deras assisted with English.MetricsAuthor Information Virginie Vlaeminck-Guillem Department of Medical Unit of Molecular Oncology and Transfer, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France Institute of Functional Genomics of Lyon , Lyon, France More articles by this author Marian Devonec Department of Urology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France More articles by this author Marc Colombel Department of Urology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France More articles by this author Claire Rodriguez-Lafrasse Department of Medical Unit of Molecular Oncology and Transfer, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France More articles by this author Myriam Decaussin-Petrucci Department of Pathology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France Institute of Functional Genomics of Lyon , Lyon, France More articles by this author Alain Ruffion Department of Urology, Medical Faculty of Lyon 1 University, Lyon, France Department of Hospices Civils of Lyon, Medical Faculty of Lyon 1 University, Lyon, France Institute of Functional Genomics of Lyon , Lyon, France Financial interest and/or other relationship with Allergan, Ipsen, Takeda, Astra and Medtronic. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1998839167 created "2016-06-24" @default.
• W1998839167 creator A5007578355 @default.
• W1998839167 creator A5026061623 @default.
• W1998839167 creator A5026135868 @default.
• W1998839167 creator A5049633800 @default.
• W1998839167 creator A5055024508 @default.
• W1998839167 creator A5063078592 @default.
• W1998839167 date "2011-04-01" @default.
• W1998839167 modified "2023-10-02" @default.
• W1998839167 title "Urinary PCA3 Score Predicts Prostate Cancer Multifocality" @default.
• W1998839167 cites W1562365902 @default.
• W1998839167 cites W1749151982 @default.
• W1998839167 cites W1971886854 @default.
• W1998839167 cites W1987998253 @default.
• W1998839167 cites W1996587036 @default.
• W1998839167 cites W2006215550 @default.
• W1998839167 cites W2014966452 @default.
• W1998839167 cites W2017828300 @default.
• W1998839167 cites W2018825309 @default.
• W1998839167 cites W2023922025 @default.
• W1998839167 cites W2024097324 @default.
• W1998839167 cites W2054217474 @default.
• W1998839167 cites W2091288012 @default.
• W1998839167 cites W2097876373 @default.
• W1998839167 cites W2098905361 @default.
• W1998839167 cites W2103560522 @default.
• W1998839167 cites W2107818553 @default.
• W1998839167 cites W2132803044 @default.
• W1998839167 cites W2138084306 @default.
• W1998839167 cites W2141655009 @default.
• W1998839167 cites W2145491305 @default.
• W1998839167 cites W2156438249 @default.
• W1998839167 cites W2162061149 @default.
• W1998839167 cites W2169385858 @default.
• W1998839167 doi "https://doi.org/10.1016/j.juro.2010.11.072" @default.
• W1998839167 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21334023" @default.
• W1998839167 hasPublicationYear "2011" @default.
• W1998839167 type Work @default.
• W1998839167 sameAs 1998839167 @default.
• W1998839167 citedByCount "30" @default.
• W1998839167 countsByYear W19988391672012 @default.
• W1998839167 countsByYear W19988391672013 @default.
• W1998839167 countsByYear W19988391672014 @default.
• W1998839167 countsByYear W19988391672015 @default.
• W1998839167 countsByYear W19988391672017 @default.
• W1998839167 countsByYear W19988391672018 @default.
• W1998839167 countsByYear W19988391672019 @default.
• W1998839167 countsByYear W19988391672021 @default.
• W1998839167 countsByYear W19988391672022 @default.
• W1998839167 crossrefType "journal-article" @default.
• W1998839167 hasAuthorship W1998839167A5007578355 @default.
• W1998839167 hasAuthorship W1998839167A5026061623 @default.
• W1998839167 hasAuthorship W1998839167A5026135868 @default.
• W1998839167 hasAuthorship W1998839167A5049633800 @default.
• W1998839167 hasAuthorship W1998839167A5055024508 @default.
• W1998839167 hasAuthorship W1998839167A5063078592 @default.
• W1998839167 hasConcept C121608353 @default.
• W1998839167 hasConcept C126322002 @default.
• W1998839167 hasConcept C126894567 @default.
• W1998839167 hasConcept C143998085 @default.
• W1998839167 hasConcept C2776235491 @default.
• W1998839167 hasConcept C2780192828 @default.
• W1998839167 hasConcept C29456083 @default.
• W1998839167 hasConcept C71924100 @default.
• W1998839167 hasConcept C77411442 @default.
• W1998839167 hasConcept C87874733 @default.
• W1998839167 hasConceptScore W1998839167C121608353 @default.
• W1998839167 hasConceptScore W1998839167C126322002 @default.
• W1998839167 hasConceptScore W1998839167C126894567 @default.
• W1998839167 hasConceptScore W1998839167C143998085 @default.
• W1998839167 hasConceptScore W1998839167C2776235491 @default.
• W1998839167 hasConceptScore W1998839167C2780192828 @default.
• W1998839167 hasConceptScore W1998839167C29456083 @default.
• W1998839167 hasConceptScore W1998839167C71924100 @default.
• W1998839167 hasConceptScore W1998839167C77411442 @default.
• W1998839167 hasConceptScore W1998839167C87874733 @default.
• W1998839167 hasIssue "4" @default.
• W1998839167 hasLocation W19988391671 @default.
• W1998839167 hasLocation W19988391672 @default.
• W1998839167 hasOpenAccess W1998839167 @default.
• W1998839167 hasPrimaryLocation W19988391671 @default.
• W1998839167 hasRelatedWork W1980245127 @default.
• W1998839167 hasRelatedWork W2088197194 @default.
• W1998839167 hasRelatedWork W2127440557 @default.
• W1998839167 hasRelatedWork W2132803044 @default.
• W1998839167 hasRelatedWork W2373651588 @default.
• W1998839167 hasRelatedWork W2376423713 @default.
• W1998839167 hasRelatedWork W2591376766 @default.
• W1998839167 hasRelatedWork W2897445903 @default.
• W1998839167 hasRelatedWork W3082324229 @default.
• W1998839167 hasRelatedWork W3163649103 @default.
• W1998839167 hasVolume "185" @default.
• W1998839167 isParatext "false" @default.
• W1998839167 isRetracted "false" @default.
• W1998839167 magId "1998839167" @default.
• W1998839167 workType "article" @default.